Investors have had an appetite for cannabis stocks since recreational marijuana was legalized in Canada last year. Wall Street analysts are now taking notice, and Stifel is the latest firm to weigh in on Cronos Group Inc (NASDAQ: CRON).
The Analyst
On Thursday, Stifel analyst W. Andrew Carter initiated coverage of Cronos with a Hold rating and C$18 ($13.44 USD) price target.
Need more cannabis news? Check out all of our coverage here.
The Thesis
Carter said Cronos is well-positioned for the booming Canadian adult-use marijuana market and has the resources, capital and partnerships to potentially attack the global market in the long-term. Carter is especially optimistic about Cronos’ partnership with tobacco giant Altria Group Inc (NYSE: MO), which invested about $2 billion to help with the Cronos growth push.
With the stock up 125 percent in the past year, Carter said the market has gotten a bit ahead of itself.
“Our near-term target price for the shares suggests some downside potential given the unbridled enthusiasm that has taken hold here following the investment by Altria pushing the valuation to the top of the industry,†Carey wrote in a note.
For now, Carey said investors should remain patient and look to buy shares on any major pullback opportunities.
Carey says Cronos is also focused on delivering the same type of innovation with its cannabis vapor products that Apple, Inc. (NASDAQ: AAPL) brought to the smartphone industry when it launched the iPhone. Altria’s tobacco expertise has helped Cronos prepare for having vaping products ready for launch on day one of legalization last October.
Price Action
Cronos shares traded about 1 percent lower to $15.86 on Thursday.
Related Links:
Stifel Cautious On Aurora Cannabis Given 'Lack Of A Definitive Strategy' In US
Stifel: Canopy Growth Is The 'Best Investable Opportunity' In Cannabis
Latest Ratings for CRON
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 2019 | Initiates Coverage On | Hold | ||
| Jun 2019 | Upgrades | Underperform | Buy | |
| Apr 2019 | Initiates Coverage On | Underperform |
View More Analyst Ratings for CRON
View the Latest Analyst Ratings
See more from Benzinga
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.